SL4Y CAR-T cells

SL4Y CAR-T cells are an allogeneic, "off-the-shelf" T-cell platform designed to overcome the limitations of primary donor-derived cells in CAR-T therapy manufacture. The platform is created by immortalizing primary human T cells using *Herpesvirus saimiri* (HVS), a non-integrating simian herpesvirus, resulting in a renewable cell line that maintains the biological fidelity of primary T cells, including diploidy, polyclonal TCR repertoires, and memory-associated phenotypes. SL4Y cells are engineered using multiplex CRISPR/Cas9 technology to ablate endogenous T-cell receptors (TCR) and MHC Class I/II molecules, reducing the risk of graft-versus-host disease (GvHD) and immune rejection. Additionally, the cells incorporate an RQR8 suicide switch to allow for rapid depletion as a safety mechanism. The platform is intended to serve as a standardized foundation for iterative genetic engineering and the development of universal cellular immunotherapies for B-cell malignancies and other cancers.

Other names

SL4Y cellsSL-4Y cellsSL 4Y cellsSL4Y platformSL-4Y platformSL 4Y platform